Analyst Yuko Oku of Morgan Stanley maintained a Hold rating on GRAIL Inc, with a price target of $85.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Yuko Oku’s rating is based on a combination of factors that reflect both the potential and the risks associated with GRAIL Inc’s multi-cancer early detection test, Galleri. While there is significant long-term potential for Galleri, the adoption of such novel technologies faces challenges, particularly in terms of regulatory approval and reimbursement pathways. Additionally, despite recent financing efforts that have bolstered the company’s balance sheet, GRAIL Inc must continue to manage its cash burn carefully as it approaches critical milestones such as NHS-Galleri data, FDA approval, and broader reimbursement.
With the stock price having risen significantly due to positive business developments, including expanded access through a partnership with Quest and promising trial data, Yuko Oku views the current valuation as fair. The potential for further stock appreciation is contingent upon successfully navigating these key milestones. Therefore, the Hold rating reflects a balanced view of the company’s prospects and the inherent risks involved.
In another report released on November 13, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $92.00 price target.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GRAL in relation to earlier this year.